TRIM25 is reported to be upregulated in endometrial cancer, ovary cancer, prostate cancer, lung cancer and breast cancer and its overexpression is associated with poor prognosis, at least for breast cancer patients [257,258,259,260,261]. Here, TRIM25 is linked to breast carcinoma.